Frederic Guerard Buys Shares of LENZ Therapeutics, Inc. $LENZ
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Frederic Guerard, insider at LENZ Therapeutics, Inc. ($LENZ), bought 22,100 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
LENZ Therapeutics, Inc. Stock Up 29.7%
Shares of LENZ Therapeutics, Inc. ($LENZ) traded around $6.63 on Tuesday, up 29.7% for the day.
LENZ Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Get LENZ Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LENZ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.